How many clinical trials are tracked for Lung Diseases, Obstructive?

7 trials are tracked, 0 with published results.

Lung Diseases, Obstructive Research

Lung Diseases, Obstructive: current evidence & treatments

Structured physical activity and exercise interventions show significant benefits in obstructive lung diseases. In asthma, structured physical activity improves FEV1% predicted by 5.79 and quality of life (PAQLQ) ¹. In idiopathic pulmonary fibrosis, structured exercise improves 6-minute walk distance by 38.62 m ². For COPD, water-based Liuzijue exercise is most effective for improving FEV1%pred (MD 9.51) ²³, and IoT-assisted pulmonary rehabilitation protocols are being investigated ⁵. COPD patients also exhibit heightened sympathetic nerve activity compared to healthy adults ⁹.

Pharmacological and management strategies vary. Anti-inflammatory reliever therapy (AIR) reduces severe exacerbations compared to SABA-only in asthma ¹⁴. Casirivimab plus imdevimab reduces hospitalization or death in COVID-19 patients with and without asthma ⁶. In IPF, pirfenidone reduces lung cancer incidence by 73% (RR 0.39) ¹⁷. For pulmonary embolism, ultrasound-facilitated catheter-directed alteplase reduces early recurrence ²⁰. Telemedicine strategies, especially combined approaches, improve asthma control and quality of life ¹⁸. However, 14% of COPD patients decline or discontinue long-term PAP therapy ¹⁰.

Genetic and environmental factors contribute to disease risk. HLA-DPA1 and HLA-DPB1 are downregulated in pediatric asthma with high diagnostic value ¹¹. FAM13A variants influence tissue destruction in COPD and fibrotic remodeling in pulmonary fibrosis ¹³. Maternal free vitamin D is linked to offspring asthma risk ⁷. Prenatal beta-2-agonist exposure is associated with increased ASD risk (aOR 1.34) ¹⁶. Ultra-processed food consumption is associated with asthma in children ³. PM2.5 exposure may increase asthma risk in susceptible individuals ²². The respiratory microbiome offers insights for precision treatment ²¹.

Structured physical activity improves FEV1% predicted by 5.79 in asthma ¹ and 6-minute walk distance by 38.62 m in IPF ²; water-based Liuzijue is best for COPD FEV1%pred (MD 9.51) ²³.

Anti-inflammatory reliever therapy reduces severe exacerbations vs SABA-only in asthma ¹⁴; casirivimab plus imdevimab reduces hospitalization/death in COVID-19 ⁶; pirfenidone reduces lung cancer incidence in IPF (RR 0.39) ¹⁷.

Telemedicine combined strategies improve asthma control ¹⁸; 14% of COPD patients decline/discontinue PAP therapy ¹⁰.

HLA-DPA1 and HLA-DPB1 are downregulated in pediatric asthma ¹¹; FAM13A variants affect COPD and pulmonary fibrosis ¹³; maternal vitamin D and prenatal beta-2-agonists influence offspring asthma/ASD risk [7,16].

Ultra-processed food and PM2.5 exposure are associated with asthma risk [3,22]; respiratory microbiome may guide precision treatment ²¹.